Cohort-based germline variant characterization is the standard approach for pathogenic variant discovery in clinical and research samples. However, the impact of cohort size on the molecular diagnostic yield of joint genotyping is largely unknown.
Head-to-head comparison of the molecular diagnostic yield of joint genotyping in two cohorts of 239 cancer patients in the absence and then in the presence of 100 additional germline exomes.
In 239 testicular cancer patients, 4 (7.4%, 95% confidence interval [CI]: 2.1-17.9) of 54 pathogenic variants in the cancer predisposition and American College of Medical Genetics and Genomics (ACMG) genes were missed by one or both computational runs of joint genotyping. Similarly, 8 (12.1%, 95% CI: 5.4-22.5) of 66 pathogenic variants in these genes were undetected by joint genotyping in another independent cohort of 239 breast cancer patients. An exome-wide analysis of putative loss-of-function (pLOF) variants in the testicular cancer cohort showed that 162 (8.2%, 95% CI: 7.1-9.6) pLOF variants were only detected in one analysis run but not the other, while 433 (22.0%, 95% CI: 20.2-23.9%) pLOF variants were filtered out by both analyses despite having sufficient sequencing coverage.
Our analysis of the standard germline variant detection method highlighted a substantial impact of concurrently analyzing additional genomic data sets on the ability to detect clinically relevant germline pathogenic variants.
Genetics in medicine : official journal of the American College of Medical Genetics. 2021 Feb 02 [Epub ahead of print]
Sabrina Y Camp, Eric Kofman, Brendan Reardon, Nathanael D Moore, Abdullah M Al-Rubaish, Mohammed Aljumaan, Amein K Al-Ali, Eliezer M Van Allen, Amaro Taylor-Weiner, Saud H AlDubayan
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Internal Medicine Residency Program, University of Cincinnati, Cincinnati, OH, USA., College of Medicine, Imam Abdulrahman bin Faisal University, Dammam, Saudi Arabia., Cancer Program, The Broad Institute of MIT and Harvard, Cambridge, MA, USA. ., Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. .